|
Recipient age at SCT (years, range)
|
61 (50–78)
|
61 (50–77)
|
60 (50–73)
|
0.584
|
|
Recipient gender, n (%)
|
0.707
|
|
Male
|
1386 (54 %)
|
387 (53.7 %)
|
62 (58 %)
| |
|
Female
|
1177 (46 %)
|
334 (46.3 %)
|
45 (42 %)
| |
|
Year of SCT (median), year (%)
|
2011 (00–13)
|
2011 (02–13)
|
2009 (00–13)
|
0.001
|
|
Interval from diagnosis to SCT (days)
|
212
|
250
|
295
|
0.0001
|
|
Median follow-upa (months, range)
|
24 (1–150)
|
24 (1–139)
|
34 (3–117)
|
0.042
|
|
Donor age (years, range)
|
33 (16–61)
|
36 (20–61)
|
35 (20–55)
|
0.02
|
|
Donor gender, n (%)
|
<10−4
|
|
Male
|
1845 (73 %)
|
463 (65.2 %)
|
69 (64.5 %)
| |
|
Female
|
682 (27 %)
|
247 (34.8 %)
|
38 (35.5 %)
| |
|
Female donor to male recipient, n (%)
|
281 (11.1 %)
|
106 (15 % )
|
17 (16 % )
|
0.01
|
|
Diagnosis, n (%)
|
0.001
|
|
De novo AML
|
1805 (70.3 %)
|
527 (72.9 %)
|
60 (55.6 %)
| |
|
Secondary AML
|
762 (29.7 %)
|
196 (27.1 %)
|
48 (44.4 %)
| |
|
Cytogenetics in de novo AML, n (% of available data)
|
0.235
|
|
Good
|
75 (9.2 %)
|
15 (5.9 %)
|
2 (7.1 %)
| |
|
Intermediate
|
545 (67.2 %)
|
183 (72 %)
|
23 (82 %)
| |
|
Poor
|
191 (23.5 %)
|
56 (22 %)
|
3 (10.7 %)
| |
|
Not available/failed
|
994 (55 %)
|
273 (51.8 %)
|
32 (53.3 %)
| |
|
Disease status at SCT, n (%)
| | | |
0.0002
|
|
CR1
|
1413 (55 %)
|
333 (46.1 %)
|
48 (44.4 %)
| |
|
≥CR2
|
504 (19.7 %)
|
171 (23.6 %)
|
25 (23.2 %)
| |
|
Active disease
|
650 (25.3 %)
|
219 (30.3 %)
|
35 (32.4 %)
| |
|
Source of SC, n (%)
|
0.173
|
|
BM
|
154 (6 %)
|
56 (7.8 %)
|
9 (8.3 %)
| |
|
PB
|
2413 (94 %)
|
667 (92.2 %)
|
99 (91.7 %)
| |
|
Conditioning, n (%)
|
0.02
|
|
Chemo alone
|
1836 (71.5 %)
|
550 (76.1 %)
|
84 (77.8 %)
| |
|
Low TBI
|
731 (28.5 %)
|
173 (23.9 %)
|
24 (22.2 %)
| |
|
In vivo T cell depletion, n (%)
|
<10−4
|
|
No
|
672 (26.4 %)
|
121 (16.9 %)
|
15 (14.0 %)
| |
|
ATG
|
1460 (57.5 %)
|
468 (65.2 %)
|
59 (55.1 %)
| |
|
Campath
|
409 (16.1 %)
|
129 (18.0 %)
|
33 (30.8 %)
| |
|
Post-transplant GVHD prophylaxis
| | | |
0.07
|
|
CsA
|
504 (19.9 %)
|
135 (18.8 %)
|
27 (25.5 %)
| |
|
CsA/FK 506 + MTX
|
517 (20.4 %)
|
177 (24.7 %)
|
16 (15.1 %)
| |
|
CsA/FK 506 + MMF
|
1353 (53.4 %)
|
353 (49.2 %)
|
53 (50 %)
| |
|
Other
|
160 (6.3 %)
|
53 (7.4 %)
|
10 (9.4 %)
| |
|
Missing
|
33
|
5
|
2
| |
|
Karnosky at SCT, n (%)
| | | |
0.47
|
|
≤80 %
|
173 (6.7 %)
|
42 (5.8 %)
|
9 (8.4 %)
| |
|
>80 %
|
2231 (86.9 %)
|
641 (88.7 %)
|
91 (84.2 %)
| |
|
Missing
|
163 (6.4 %)
|
40 (5.5 %)
|
8 (7.4 %)
| |
|
Patient positive CMV serology, n (%)
|
1634 (64.9 %)
|
492 (69.1 %)
|
67 (63.8 %)
|
0.10
|
|
CMV risk, n (%)
| | | |
0.029
|
|
Low
|
695 (27.8 %)
|
155 (21.9 %)
|
26 (24.8 %)
| |
|
Intermediate
|
1072 (42.8 %)
|
316 (44.7 %)
|
47 (44.8 %)
| |
|
High
|
734 (29.4 % )
|
236 (33.4 %)
|
32 (30.5 %)
| |
